Tenderwize
Back to tender search

Open-house drug rebate agreements for aflibercept 40 mg/ml

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Oct 31, 2027 · 345 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Aflibercept, in der Wirkstärke 40 mg/ml, ATC S01LA05

52/100

Opportunity Score

Needs reviewHigh complexity
SuppliesOpen
Why this score?

Opportunity

52 / 100

Complexity

68 / 100

Risk factors

The notice provides no value or volume information, and non-exclusive participation does not guarantee orders or revenu...

Open-house contracts may end automatically if exclusive rebate contracts enter into force.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Oct 31, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under §§130a(8) and 130c(1) SGB V for Aflibercept 40 mg/ml, ATC S01LA05.
  • Open-house model with uniform contractual conditions and access procedures for all participating pharmaceutical companies.
Show full summary

Open-house, non-exclusive pharmaceutical rebate agreements for Aflibercept 40 mg/ml (ATC S01LA05), offered by AOK Rheinland-Pfalz/Saarland to all interested pharmaceutical companies meeting the stated marketability requirements. No selection decision or individual negotiations are envisaged. The arrangement runs for up to 24 months from 1 January 2026, but contracts may be terminated or automatically ended if exclusive rebate contracts are introduced. Contract documents and commercial terms were not provided for analysis. The structured notice gives a final deadline of 31 October 2027, while the notice text specifies earlier receipt deadlines for the initial and monthly entry dates.

Risks

The notice provides no value or volume information, and non-exclusive participation does not guarantee orders or revenu...

Open-house contracts may end automatically if exclusive rebate contracts enter into force.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only pharmaceutical companies may participate.
  • Medicines must be authorised and marketable in Germany.
  • Marketability may be demonstrated through listing in the Lauer-Taxe.

Buyer

Lots (1)

LOT-0001

Aflibercept pharmaceutical rebate agreements

Non-exclusive open-house rebate agreements for medicines containing Aflibercept at 40 mg/ml, ATC S01LA05. All interested pharmaceutical companies may join under uniform conditions without individual negotiation. Medicines on the BfArM children’s medicines list under §35(5a) SGB V are excluded.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Dec 2025 - Dec 2027

Category

Pharmaceutical products

Deadline

Deadline Oct 31, 2027

Procurement Details

Publication date
16 Nov 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
762030-2025

Documents (1)

Similar tenders

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy